US extends expiration dates for Johnson & Johnson Covid vaccine by 6 weeks

[ad_1]


Johnson & Johnson said Thursday that U.S. regulators extended the expiration date on millions of doses of its COVID-19 vaccine by six weeks.


The company said a Food and Drug Administration review concluded the shots remain safe and effective for at least 4 1/2 months. In February, the FDA originally authorised J&J’s vaccine for up to three months when stored at normal refrigeration levels.





Thursday’s announcement comes after state officials warned that many doses in storage would expire before the end of the month.


Vaccine expiration dates are based on information from drugmakers on how long the shots stay at the right strength. J&J said the FDA added six weeks based on data from ongoing studies assessing the vaccine’s stability.


The FDA has been reviewing expiration dates on all three U.S. authorised vaccines as have continued to test batches in the months since the shots first rolled out. The vaccines from Pfizer and Moderna, authorized in December, have a six-month shelf life.


The J&J extension will help maintain vaccine supplies even as the number of Americans getting shots has slipped. The country averaged about 800,000 new injections per day last week.


That’s down from a high of nearly 2 million daily shots two months ago. Government officials and have turned to incentives to encourages shots, including paid time off to USD 1 million lottery prizes.


As vaccinations have slowed it’s become clear the U.S. is unlikely to meet President Joe Biden’s goal to have 70 per cent of adults partially vaccinated by July 4. Roughly 64 per cent of Americans older than 18 have had at least one dose, according to the Centers for Disease Control and Prevention.


J&J’s vaccine was highly anticipated because of its one-and-done formulation and easy-to-ship refrigeration. The shot was expected to play a key role in vaccination campaigns in rural areas and low-income countries with limited health care infrastructure.


But rival drugmakers Pfizer and Moderna, which started shipping shots months earlier, have already supplied more than enough doses to meet U.S. demand. More than 129 million Americans have been fully vaccinated with the companies’ two-dose shots.


By comparison, just 11 million Americans have been vaccinated with the J&J shot. About 10 million more J&J doses have been sent to states, according to the CDC.


Use of J&J’s vaccine has been hurt by links to a rare blood clot disorder. That issue led U.S. health officials to pause use of the shot for an 11-day review. Officials lifted the hold in late April after concluding that the vaccine’s benefits outweighed its risks

J&J’s rollout has also been slowed by contamination problems at a Baltimore factory that helps make the shots.


The facility was shuttered after an FDA inspection uncovered unsanitary conditions and other problems in April. None of the vaccines made there have been distributed.

(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)

Dear Reader,

Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.

We, however, have a request.

As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.

Support quality journalism and subscribe to Business Standard.

Digital Editor



[ad_2]

Source link

Leave a Reply

Your email address will not be published. Required fields are marked *